Evidence map›Paper›PMID 36188028›Full record

ArticleClinical case reports2022

Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.

Stephanie Lakritz, Peter A Forsberg, Daniel W Sherbenou, Tomer M Mark

Abstract readCase Reports
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stephanie LakritzDepartment of Medicine, Division of Hematology University of Colorado School of Medicine Aurora Colorado USA.
Peter A ForsbergDepartment of Medicine, Division of Hematology University of Colorado School of Medicine Aurora Colorado USA.ORCID https://orcid.org/0000-0003-3248-7530
Daniel W SherbenouDepartment of Medicine, Division of Hematology University of Colorado School of Medicine Aurora Colorado USA.
Tomer M MarkDepartment of Medicine, Division of Hematology University of Colorado School of Medicine Aurora Colorado USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed multiple myeloma along with a history of systemic mastocytosis who developed evidence of an autoimmune enteropathy shortly after initiating lenalidomide based therapy.

Indexed as

chemotherapyoncologypharmacologyplasma cell neoplasms

Identifiers

PMID36188028
PMCPMC9483819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.